Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
← Psychiatry indexChapter sections
OverviewAetiologyPathophysiologyClinical features and red flagsInvestigationsDifferential diagnosisManagementComplicationsMonitoring and follow-upSpecial situationsCommon pitfallsQuestionsSources
Full textbook13 sectionsOpen only what you need
Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.

Catatonia recognition and management

Psychiatry · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Malignant or medically complicated catatonia

Catatonic signs accompanied by fever, delirium, autonomic instability, severe rigidity, dehydration, thrombosis, aspiration or organ injury can deteriorate rapidly and requires critical supportive care and urgent specialist treatment.

Action: Assess ABCDE, glucose, temperature, hydration and muscle injury, discontinue dopamine antagonists when malignant catatonia or neuroleptic malignant syndrome is possible, and involve liaison psychiatry, medicine, neurology and anaesthesia. Begin benzodiazepine treatment and arrange urgent ECT evaluation without awaiting every test.

Overview

Identify catatonia through positive motor, behavioural and speech signs, support nutrition and complication prevention, investigate psychiatric, neurological and medical causes, and use a measured lorazepam trial and timely electroconvulsive therapy without harmful diagnostic delay.

Catatonia alters movement, volition, speech and response to the environment. Examine rather than relying on a general impression. Observe spontaneous activity and speech, then test gaze, tone, posture, passive movement, resistance, automatic obedience, imitation and response to simple commands using respectful technique. Stuporous presentations may show immobility, mutism, staring, posturing and negativism. Excited presentations show excessive non-purposeful activity, impulsivity or combativeness. Echolalia, echopraxia, stereotypy, mannerism, grimacing and waxy flexibility are particularly informative positive signs.

The syndrome occurs with severe depression, mania and schizophrenia-spectrum illness, but also encephalitis, epilepsy, neurodegeneration, metabolic disease, infection, toxins and medication withdrawal. The first episode, unusual age or rapid cognitive and neurological change deserves a broad search. Review recent antipsychotics, benzodiazepine withdrawal, substances and systemic symptoms. Anti-NMDA-receptor encephalitis is an important possibility when psychiatric change evolves into seizures, memory impairment, dyskinesia,

Practice

Two practice questions

Your practice draft is saved in this browser.

Question 1 of 2
0 correct
PsychiatryOriginal SBA

Positive catatonic sign

A mute patient keeps an examiner-positioned arm raised for several minutes and repeatedly copies the examiner's hand movements. Which interpretation is most appropriate?

Choose one answer, then submit
← Rapid synopsisBack to overviewAll Psychiatry topics →
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • British Association for Psychopharmacology catatonia guidelineUK dosing authority for the specialist-led off-label lorazepam challenge and guidance on investigations, complications, malignant catatonia and ECT.
  • NICE TA59 electroconvulsive therapy recommendationsECT as rapid treatment for severe or life-threatening catatonia when other treatments fail.
  • NICE CG178 psychosis and schizophrenia recommendationsPsychosis assessment, physical care and ECT positioning within schizophrenia treatment.
  • Lorazepam injection summary of product characteristicsFormulation and administration safety, respiratory cautions, interactions and monitoring; not the dosing authority for off-label catatonia treatment.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateComplete draftClinical stateAwaiting reviewJurisdictionUnited Kingdom
reduced consciousness
or autonomic instability.

Medical care begins immediately. Record observations, glucose, intake and output, weight, swallowing and hydration. Examine for infection, injury, pressure damage, contracture, urinary retention, constipation and venous thrombosis. Provide fluids and nutrition safely, pressure-area care, physiotherapy positioning and thromboprophylaxis according to individual bleeding and mobility risk. Maintain communication: a mute or apparently unresponsive person may remain aware. Explain each examination and preserve privacy and dignity.

A structured catatonia assessment provides a reproducible baseline. Lorazepam challenge use for catatonia is specialist-led and off-label: the BAP guideline describes 1 mg to 2 mg intravenously or intramuscularly, or 2 mg orally, followed by repeat objective examination after the route-appropriate interval. The current product SmPC informs formulation, respiratory, interaction and administration safety but is not the dosing authority for catatonia. Clear improvement supports the syndrome, while non-response does not rule it out or justify delaying ECT in severe disease.

Malignant catatonia adds fever, autonomic instability, delirium and organ injury. Neuroleptic malignant syndrome can look similar, particularly after dopamine blockade; recent drug exposure, rigidity pattern and prodrome guide but may not settle the distinction. Discontinue dopamine antagonists and use critical supportive care. ECT can be life saving and should be arranged urgently when catatonia is malignant, physiological compromise is severe or benzodiazepines fail. Capacity, legal authority and anaesthetic risk need rapid coordinated assessment, not prolonged therapeutic delay.

Key points

  • Catatonia is a psychomotor syndrome identified by clusters of signs such as stupor, mutism, posturing, negativism, waxy flexibility, echophenomena, stereotypy, mannerism, grimacing or purposeless excitement.
  • Look for positive signs and demonstrate them carefully; immobility or silence alone can reflect coma, delirium, severe depression, neurological disease, sedation or deliberate non-participation.
  • Use a structured bedside scale to record the same signs before and after treatment and across shifts rather than describing the patient merely as withdrawn.
  • Assess hydration, nutrition, swallowing, skin, bladder and bowel, venous thrombosis, infection, contracture and aspiration from the first encounter.
  • Investigate mood disorder, psychosis, medicines and withdrawal, seizures, encephalitis, metabolic disturbance and systemic illness according to the clinical phenotype.
  • A lorazepam challenge for catatonia is specialist-led and off-label; use the BAP guideline as the dosing authority and the current lorazepam SmPC for formulation safety, while recognising that a negative or partial response does not exclude severe disease.
  • Electroconvulsive therapy is time critical for malignant, life-threatening or benzodiazepine-resistant catatonia and referral should begin while supportive care continues.

Aetiology

01

Mood disorders

Severe depression and mania can produce stuporous or excited catatonia, sometimes with psychosis, poor intake and malignant autonomic deterioration.

02

Psychotic disorders

Schizophrenia-spectrum illness can include acute or persistent catatonic motor and behavioural signs that require treatment beyond antipsychotic escalation.

03

Neurological and medical illness

Encephalitis, epilepsy, neurodegeneration, infection, metabolic disease and toxins can disrupt motor control, volition and responsiveness through different mechanisms.

04

Medicine and withdrawal effects

Dopamine blockade, benzodiazepine withdrawal and other exposure changes can precipitate, worsen or mimic catatonia and shape immediate medicine safety.

Pathophysiology

  1. 1
    Motor network dysregulation

    Disrupted cortical and subcortical control of movement and initiation may produce immobility, abnormal persistence, automatic behaviour or purposeless excitation.

  2. 2
    Inhibitory signalling disturbance

    Altered GABA-mediated control is consistent with rapid benzodiazepine response in some patients, though response varies by severity and cause.

  3. 3
    Dopamine and glutamate imbalance

    Changes in dopaminergic and glutamatergic signalling may contribute to motor rigidity, salience disturbance and vulnerability to dopamine-antagonist worsening.

  4. 4
    Malignant physiological cascade

    Sustained muscle activity, immobility, poor intake and autonomic instability drive dehydration, hyperthermia, thrombosis, aspiration and organ injury.

Clinical features and red flags

Stuporous pattern

Reduced movement and speech occurs with staring, posturing, negativism, withdrawal or abnormal resistance rather than simple sleepiness alone.

Excited pattern

Excessive purposeless motor activity, impulsivity and repetitive behaviour alternates with or replaces immobility and can cause serious exhaustion or injury.

Echo and imitation signs

Repetition of another person's speech or movements provides positive psychomotor evidence when observed in a consistent clinical context.

Malignant transition

Fever, delirium, autonomic lability and laboratory evidence of muscle or organ injury mark life-threatening physiological deterioration.

Neurological context

Seizure, dyskinesia, focal findings, rapid memory loss or fluctuating consciousness indicates neurological investigation beyond a primary psychiatric formulation.

Red flags requiring action

  • Fever, labile blood pressure, tachycardia, delirium or rising creatine kinase with catatonic signs indicates malignant physiology and potential organ failure.
  • New seizure, dyskinesia, focal neurology, memory loss or autonomic fluctuation raises autoimmune encephalitis or another neurological disorder.
  • Absent intake, urinary retention, immobility, pressure injury, hypoxia or suspected thrombosis requires active medical prevention and treatment.

Investigations

  1. 01
    Structured catatonia examinationFirst step
    Why
    Record defined motor, speech, behavioural and response signs at baseline and serially.
    Interpretation and limitations
    Multiple positive signs support the syndrome and allow objective change measurement; immobility and mutism without examination remain diagnostically non-specific.
  2. 02
    Physiological complication screen
    Why
    Assess observations, glucose, hydration, swallowing, skin, bladder, bowel, thrombosis and muscle injury.
    Interpretation and limitations
    Abnormal physiology or organ injury increases urgency and determines medical support; creatine kinase alone cannot separate malignant catatonia from neuroleptic malignant syndrome.
  3. 03
    Medicine and syndrome timeline
    Why
    Relate catatonic signs to mood, psychosis, dopamine blockade, withdrawal, infection, substances and systemic illness.
    Interpretation and limitations
    A catatonic prodrome and recent treatment exposure shape the differential, but overlapping mechanisms may coexist and require cautious management.
  4. 04
    Neurological investigation
    Why
    Identify encephalitis, non-convulsive seizure, structural disease and inflammatory or metabolic causes.
    Interpretation and limitations
    Select EEG, MRI, cerebrospinal fluid and antibody or infectious tests from the phenotype; early normal results do not

Differential diagnosis

01

Hypoactive delirium

Inattention, fluctuating arousal and systemic illness can resemble stupor, while delirium and catatonia may occur together and both require treatment.

02

Neuroleptic malignant syndrome

Recent dopamine blockade, rigidity, fever and autonomic instability overlap substantially, making exposure chronology and prodrome important but not always decisive.

03

Non-convulsive status epilepticus

Impaired responsiveness, subtle movement and fluctuating behaviour may require urgent EEG rather than attribution to a psychiatric motor syndrome alone.

04

Locked-in or movement disorder

Brainstem disease, severe parkinsonism, dystonia and other neurological states can limit movement while preserving awareness through different examination findings.

05

Voluntary non-engagement

A conscious decision not to speak lacks the characteristic cluster of posturing, echo, tone and automatic motor signs, though communication remains respectful.

Management

01Suspected catatoniaConfirm signs and protect the bodyFirst stepMutism, immobility, posturing, negativism, echophenomena or unexplained motor excitement is present.+
  1. 1Use a structured bedside examination to document positive signs and assess awareness, physiology, intake, swallowing, injury and immediate complications.
  2. 2Review mood, psychosis, medicines, withdrawal, substances, infection and neurological features and obtain targeted blood, ECG, imaging, EEG or fluid tests.
  3. 3Begin hydration, nutrition, pressure, mobility and thrombosis care and involve liaison psychiatry and medical teams without waiting for diagnostic certainty.
02Lorazepam pathwayChallenge, measure and treatCatatonia is clinically likely and benzodiazepine risk has been assessed.+
  1. 1Record baseline scale items, observations, respiratory vulnerability and current sedatives before a specialist prescribes the off-label

Complications

01

Dehydration and malnutrition

Reduced intake and swallowing difficulty cause renal, electrolyte and nutritional harm and can make anaesthesia or medication less safe.

02

Thrombosis and pressure injury

Prolonged immobility promotes venous thromboembolism, skin breakdown, painful contractures and severe deconditioning unless active prevention and repositioning begins early.

03

Aspiration and infection

Impaired swallowing, pooled secretions, immobility and reduced cough increase pneumonia risk while urinary retention and catheters promote infection.

04

Malignant organ failure

Hyperthermia, autonomic instability and muscle injury can progress to rhabdomyolysis, arrhythmia, renal failure, shock and death.

05

Psychological trauma

Awareness during immobility, invasive care and restraint can leave distressing memories that require explanation, debriefing and trauma-sensitive follow-up.

Monitoring and follow-up

  • Repeat the same structured catatonia items after treatment and at least each clinical shift during instability so change is visible and reproducible.
  • Monitor temperature, pulse, blood pressure, respiratory state, hydration, intake, weight, urine, bowel function and relevant muscle and organ markers.
  • Inspect skin, positioning, range of movement, swallowing and signs of aspiration or venous thrombosis and update prevention measures daily.
  • Review benzodiazepine benefit, sedation and respiratory safety after each dose change and communicate cumulative exposure across shifts.
  • Track investigation of the underlying mood, psychotic, neurological, infectious, toxic or metabolic cause even when motor signs improve.
  • After recovery, review memory, the person's experience, relapse signs and future medicine or ECT plan with supporters and community teams where agreed.

Special situations

Positive signs carry weight

Posturing, echophenomena and waxy flexibility are more discriminating than silence or reduced activity considered without a directed examination.

Awareness may persist

People can later recall events during apparent unresponsiveness, so explanation, consent attempts and respectful care remain essential throughout.

Excitement is still catatonia

Purpose-free agitation and impulsivity may alternate with stupor and should not be mistaken automatically for mania or hostility.

Response supports not proves

Improvement after lorazepam strengthens the syndrome diagnosis but does not identify whether mood, psychosis, encephalitis or another cause underlies it.

ECT can be urgent medicine

In malignant or medically deteriorating catatonia, ECT is a time-sensitive potentially life-saving treatment rather than a distant last resort.

Common pitfalls

  1. 01

    Calling mutism deliberate refusal before examining for posturing, negativism and other catatonic signs.

  2. 02

    Assuming catatonia occurs only in schizophrenia and omitting mood, neurological and medical causes.

  3. 03

    Waiting for complete investigation before preventing dehydration, pressure injury, thrombosis and aspiration.

  4. 04

    Using an elevated creatine kinase to distinguish neuroleptic malignant syndrome from malignant catatonia absolutely.

  5. 05

    Escalating antipsychotics while malignant catatonia or neuroleptic malignant syndrome remains unresolved.

  6. 06

    Allowing a negative lorazepam challenge to delay ECT referral during physiological deterioration.

  • Avoid reflexive antipsychotic initiation until catatonia, malignant catatonia and neuroleptic malignant syndrome have been assessed by an experienced specialist.
    • Recent dopamine blockade with hyperthermia and rigidity creates overlap with neuroleptic malignant syndrome and makes further antipsychotic dosing hazardous.
  • Excited, impulsive or repetitive motor behaviour can cause exhaustion and accidental injury even when the person is not stuporous.
    • end assessment if signs progress.
  • 05
    Measured lorazepam challenge
    Why
    Test for objective short-interval improvement in a reproducible set of catatonic signs.
    Interpretation and limitations
    A clear response supports catatonia, while a partial or absent response cannot safely postpone ECT consideration in severe or malignant illness.
    • BAP-guided challenge dose.
  • 2Give the agreed route and repeat the same signs after the BAP route-specific interval, documenting objective change, sedation and physiological response.
  • 3Continue specialist-guided benzodiazepine treatment when beneficial while pursuing the cause and preparing ECT promptly if response is inadequate or severity is high.
    • 03Malignant courseProvide critical support and urgent ECTFever, autonomic instability, delirium or organ injury complicates the catatonic syndrome.+
    1. 1Discontinue dopamine antagonists, use critical ABCDE support and treat dehydration, hyperthermia, thrombosis, aspiration and rhabdomyolysis.
    2. 2Investigate neuroleptic malignant syndrome, encephalitis, seizure, sepsis and toxic or metabolic causes in parallel with psychiatric treatment.
    3. 3Arrange urgent ECT assessment with anaesthesia and the lawful consent or capacity process, avoiding delay after an incomplete benzodiazepine response.
    Key medicines and prescribing safety1 treatment · regimens, roles and cautions+
    A specialist-led off-label diagnostic and therapeutic benzodiazepine trial for suspected catatonia, with subsequent dosing determined by objective response and severity.

    Lorazepam challenge for catatonia (off-label)

    BAP guidance describes 1 mg to 2 mg intravenously or intramuscularly, or 2 mg orally, followed by repeat structured examination after the route-appropriate interval under specialist supervision.

    Use BAP guidance as the catatonia dosing authority and the current product SmPC for formulation safety; assess respiratory disease, frailty, sedatives, opioids and alcohol, and do not delay urgent ECT in malignant illness.